naphthoquinones and Opportunistic-Infections

naphthoquinones has been researched along with Opportunistic-Infections* in 3 studies

Other Studies

3 other study(ies) available for naphthoquinones and Opportunistic-Infections

ArticleYear
Failure of low-dose atovaquone prophylaxis against Pneumocystis jiroveci infection in transplant recipients.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Apr-15, Volume: 38, Issue:8

    Trimethoprim-sulfamethoxazole is the preferred agent for prophylaxis against Pneumocystis jiroveci pneumonia. Alternative agents are used in treating patients who do not tolerate this medication. We report 2 cases of prophylaxis failure in patients receiving low-dose atovaquone. We discuss the use of atovaquone as an alternative agent for prophylaxis in transplant recipients.

    Topics: Aged; Antifungal Agents; Atovaquone; Chemoprevention; Humans; Liver Transplantation; Male; Middle Aged; Naphthoquinones; Opportunistic Infections; Pneumocystis carinii; Pneumonia, Pneumocystis; Treatment Failure; Trimethoprim, Sulfamethoxazole Drug Combination

2004
A new drug (566C80) for the treatment of Pneumocystis carinii pneumonia.
    Annals of internal medicine, 1992, Jun-01, Volume: 116, Issue:11

    Topics: Antifungal Agents; Atovaquone; HIV Infections; Humans; Naphthoquinones; Opportunistic Infections; Pneumonia, Pneumocystis

1992
566C80: a potent broad spectrum anti-infective agent with activity against malaria and opportunistic infections in AIDS patients.
    Drugs under experimental and clinical research, 1991, Volume: 17, Issue:9

    566C80 is a novel hydroxynaphthoquinone with broad-spectrum anti-parasitic properties. In vitro the compound was more potent against Plasmodium falciparum than any of the established anti-malarial drugs. It had good activity against the pathogen in Aotus monkeys and was also effective in rodents infected with various drug-resistant strains of P. yoelii and P. berghei. In mice the compound showed significant activity against Toxoplasma gondii. Evaluation of the metabolic stability of 566C80 to NADPH-mediated oxidative metabolism was made using microsome preparations from a number of species including man. Unlike other quinones examined, 566C80 was shown to be inert in these assays. In Phase 1 clinical studies up to 750mg of compound were given as a single oral dose to fasted healthy male adults. This was well tolerated and the plasma drug elimination half-life was approximately 70h. In these subjects a 450mg dose gave plasma concentrations of 0.1-0.3 micrograms/ml which were achieved 1 h post-dosing and remained so for at least 7 days. Volunteers ingesting food prior to drug administration had quinone plasma levels which were significantly higher. Phase II trials are now underway to assess 566C80 for use against malaria and opportunistic infections in AIDS patients.

    Topics: 4-Quinolones; Acquired Immunodeficiency Syndrome; Adult; Animals; Anti-Infective Agents; Antimalarials; Aotus trivirgatus; Atovaquone; Dogs; Humans; Malaria, Falciparum; Male; Microsomes, Liver; Middle Aged; NADP; Naphthoquinones; Opportunistic Infections; Plasmodium; Rats; Toxoplasma

1991